GÖTEBORG, Sweden--(BUSINESS WIRE)--Vitrolife has today published its Annual Report for 2015. The document is attached to this press release and is also available on www.vitrolife.com (http://www.vitrolife.com/en/Corporate/).
Distribution of the printed versions of the annual reports to those shareholders who have requested dispatch, will be done by mail during the week commencing 11 April. The printed version of the Annual Report can be ordered on the company’s website www.vitrolife.com (http://www.vitrolife.com/en/Corporate/), by phone +46 (0)31 721 80 00 or by email info@vitrolife.com.
Gothenburg, Sweden
April 1, 2016
VITROLIFE AB (publ)
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 1, 2016 at 08:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
_________________________________________________________________________________________________________________
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 330 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
This information was brought to you by Cision http://news.cision.com
Vitrolife
Mikael Engblom, CFO
tel 46 31 721 80 14
